rs725613 — CLEC16A

CLEC16A — The Thymic Gatekeeper of Immune Tolerance

Your immune system must learn to attack pathogens without attacking your own tissues — a balancing act that starts in the thymus, where T cells are educated and self-reactive cells are eliminated. CLEC16A encodes an E3 ubiquitin ligase that controls autophagy¹¹ autophagy
the cellular recycling process that breaks down damaged proteins and organelles in thymic epithelial cells. Variants in this gene alter how effectively the thymus presents self-antigens to developing T cells — and a less effective thymic curriculum graduates more self-reactive T cells that can later attack the body's own tissues. rs725613 is one of three intronic CLEC16A variants in strong linkage disequilibrium²² linkage disequilibrium
correlated alleles inherited together as a block, so they tag the same underlying signal that have been associated with both type 1 diabetes and multiple sclerosis.

The Mechanism

CLEC16A sits within a critical gene cluster on chromosome 16p13 alongside CIITA, DEXI, and SOCS1 — genes governing immune cell differentiation and cytokine signaling. The rs725613 variant and its LD partners act as expression quantitative trait loci³³ expression quantitative trait loci
genetic variants that affect how much of a gene's mRNA is produced, rather than changing the protein sequence itself: risk allele carriers show altered CLEC16A and SOCS1 expression specifically in thymic tissue and CD4+ T cells.

The biological consequence flows through autophagy. Thymic epithelial cells (TECs) use autophagy to process and present self-antigens to developing T cells during negative selection — the process that eliminates T cells capable of attacking the body. Reducing CLEC16A expression⁴⁴ Reducing CLEC16A expression
Mouse models with reduced Clec16a in thymic epithelium produced T cells with lower autoreactivity and were protected against T1D impairs TEC autophagy, which alters the self-antigen repertoire presented to thymocytes. The result is subtly altered T-cell selection — the thymus graduates T cells with a slightly different reactivity profile, with some studies suggesting higher overall SOCS1 expression in T cells that may paradoxically affect cytokine signaling downstream.

The variant also influences CLEC16A expression in pancreatic β-cells⁵⁵ pancreatic β-cells
the insulin-producing cells destroyed in type 1 diabetes, where CLEC16A maintains mitochondrial quality control through mitophagy. Impaired mitophagy in β-cells leads to mitochondrial dysfunction and compromised insulin secretion, potentially contributing to T1D pathogenesis through a second, peripheral mechanism independent of T-cell selection.

The Evidence

The rs725613 signal was discovered in a genome-wide association study of Northern European T1D patients and replicated across populations. A Sardinian cohort study⁶⁶ Sardinian cohort study
Zoledziewska et al., Genes & Immunity, 2009 — rs725613 allele A associated with T1D (OR 1.15) and MS (OR 1.21) in 1,037 T1D cases, 1,498 MS cases, and 1,706 controls demonstrated that the same variant confers risk for both T1D and MS with comparable effect sizes — unusual evidence for a shared immunological pathway underlying two clinically distinct diseases.

Fine-mapping in a German MS cohort⁷⁷ Fine-mapping in a German MS cohort
Nischwitz et al., Acta Neurologica Scandinavica, 2011 — 31 CLEC16A SNPs genotyped in 603 MS patients and 825 controls; four intron-19 SNPs associated, rs725613 replicated confirmed rs725613 as a genuine MS risk signal and localized the effect to an ~50 kb linkage disequilibrium block within intron 19. A meta-analysis of 37 studies⁸⁸ meta-analysis of 37 studies
Tang et al., PLoS One, 2013 — 37,033 T1D cases and 54,716 controls; rs725613 G allele OR 0.71 (95% CI 0.55–0.92), p=0.01, classified as protective for T1D pooling 37,033 T1D cases confirmed the protective effect of the G allele (OR 0.71 for T1D), consistent across studies.

The G allele frequency varies markedly by ancestry: ~37% in Europeans, ~19% in East Asians, and ~59% in Africans. This population stratification helps explain why CLEC16A associations were initially discovered in European cohorts — East Asians carry fewer copies of the protective G allele and thus have a higher background rate of the risk-associated T allele at this locus.

CLEC16A variants have also been associated with at least 16 additional autoimmune conditions including systemic lupus erythematosus, celiac disease, Crohn's disease, and rheumatoid arthritis⁹⁹ systemic lupus erythematosus, celiac disease, Crohn's disease, and rheumatoid arthritis
Comprehensive review of CLEC16A function across autoimmune conditions including 18 GWAS-confirmed disease associations, underscoring the gene's broad role in immune tolerance across multiple tissues.

Practical Actions

The TT genotype (risk-allele homozygotes) carries modestly elevated odds for T1D (OR ~1.15–1.3 per allele dose) and MS (OR ~1.21 per allele dose). These are moderate effects in the context of multifactorial diseases — other genetic and environmental factors dominate absolute risk. The actionable insight is targeted monitoring: T1D and MS both have early biomarkers that enable earlier intervention when caught proactively.

For T1D, autoantibody screening (anti-GAD65, anti-IA-2, anti-ZnT8, anti-insulin) can detect pre-clinical immune activation years before β-cell destruction becomes symptomatic. For MS, familiarity with early neurological symptoms — visual changes, numbness, weakness, balance problems — enables prompt MRI and neurological evaluation. Vitamin D insufficiency is a documented modifiable risk factor for both conditions; genotype-guided vitamin D optimization is a specific, actionable step for CLEC16A risk carriers.

Interactions

rs725613 is in strong LD with rs2903692 and rs17673553 — all three mark the same intronic 16p13 haplotype block. It is also in partial LD with rs12708716, an independent CLEC16A signal with documented thymic eQTL effects on SOCS1 and DEXI. Individuals carrying risk alleles at multiple CLEC16A variants across these LD blocks may have a larger overall effect on CLEC16A expression than any single variant predicts.

The chromosome 16p13 region includes SOCS1, an inhibitor of JAK-STAT cytokine signaling. Because CLEC16A risk variants affect SOCS1 expression in thymic tissue and T cells, interactions with cytokine pathway variants in IL2RA (rs2104286), PTPN22 (rs2476601), and HLA region variants likely modulate the net autoimmune risk — though no formal compound-genotype studies have quantified these combined effects for rs725613 specifically.